Neose Technologies, Inc. has announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for a pending patent application related to its GlycoPEGylation™ technology.
The allowed U.S. claims broadly cover glycosyl-linked poly (ethylene glycol) ("PEG") conjugates of therapeutic peptides.
This is the first allowed patent application in a series of pending patent applications directed toward the company's GlycoConjugation™ technology platform.
"We believe the Notice of Allowance for these claims validates the unique nature of our technology and gives us a proprietary advantage in our primary strategy of developing next-generation therapeutic peptides," said David A. Zopf, M.D., executive vice president and chief scientific officer of Neose.
"The applicability of this patent is extensive in that it validates the patentability in the United States of Neose's technology and next-generation peptide therapeutics produced using this technology, as well as providing guidance for Neose in securing patent protection outside the United States," continued Dr. Zopf.
The issuance of this patent will complement the company's broad intellectual property portfolio.
Neose owns 25 issued U.S. patents and has licensed 68 issued U.S. patents from other institutions.